News
AURA
--
0.00%
--
Aura Biosciences GAAP EPS of -$0.44 misses by $0.01
Aura Biosciences press release (NASDAQ:AURA): Q1 GAAP EPS of -$0.44 misses by $0.01. Cash and cash equivalents and marketable securities totaling $133.3 million. Aura believes its current cash and cash
Seekingalpha · 6d ago
BRIEF-Aura Biosciences Reports Q1 2022 Results
reuters.com · 6d ago
Uber makes a big push to outshine rival Lyft, but its shares fall anyway
Uber Technologies pulled out all the stops on Wednesday to distance itself from the issues that have pulled down rival Lyft Inc. and convince investors it's the long-term leader in mobility, but its shares fell anyway.
marketwatch.com · 05/04 15:21
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
CAMBRIDGE, Mass., May 03, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of precli...
Business Wire · 05/03 20:05
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
CAMBRIDGE, Mass., May 03, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos...
Business Wire · 05/03 11:00
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 04/29 11:53
Aura Biosciences reports Q4 results
Aura Biosciences press release (NASDAQ:AURA): Q4 net loss of $11.6M As of December 31, 2021, company had cash and cash equivalents totaling $149.1M.
Seekingalpha · 03/23 21:39
BRIEF-Aura Biosciences Reports Fourth Quarter Financial Results
reuters.com · 03/23 20:22
Aura Biosciences Reports Wider Loss for Q4
MT Newswires · 03/23 17:11
Aura Biosciences receives Orphan Drug Designation for AU-011 for primary ocular melanoma
The European Commission has granted orphan drug designation to Aura Biosciences (NASDAQ:AURA) AU-011, a lead candidate for the treatment of uveal melanoma. The designation of uveal melanoma includes choroidal melanoma as well
Seekingalpha · 03/21 11:28
Aura Biosciences Announces Orphan Drug Designation Granted To AU-011 By European Commission For The Treatment Of Uveal Melanoma
Aura Biosciences Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the European
Benzinga · 03/21 11:02
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
CAMBRIDGE, Mass., March 21, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the European Commis...
Business Wire · 03/21 11:00
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22
CAMBRIDGE, Mass., March 15, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced it will host a virtual I...
Business Wire · 03/15 11:00
Aura Biosciences to Present Preclinical Data Highlighting AU‑011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting
CAMBRIDGE, Mass., March 08, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of prec...
Business Wire · 03/08 21:30
Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference
CAMBRIDGE, Mass., February 28, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los ...
Business Wire · 02/28 12:00
Aura Biosciences Highlights Will Present Data Showing Applicability Of AU-011 In Bladder Cancer At American Society Of Clinical Oncology Genitourinary Cancer Symposium Feb. 18 At 6:30 p.m. EST
Company on Track to Initiate Phase 1 Clinical Trial in 2H 2022 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ:AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug
Benzinga · 02/14 22:09
BRIEF-Aura Biosciences To Present Preclinical Data Demonstrating Applicability Of AU-011 In Bladder Cancer At 2022 ASCO Genitourinary Cancer Symposium
reuters.com · 02/14 22:06
Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium
CAMBRIDGE, Mass., February 14, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the presentation of p...
Business Wire · 02/14 22:00
BRIEF-Adage Capital Partners Dissolves Share Stake In 3M, Ups in GE, American Express
reuters.com · 02/14 16:05
Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., February 09, 2022--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los ...
Business Wire · 02/09 13:00
Webull provides a variety of real-time AURA stock news. You can receive the latest news about Aura Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AURA
Aura Biosciences, Inc. is a clinical-stage biotechnology company. The Company operates a platform, which focuses on ocular and urologic oncology. Its platform enables targeting of a range of solid tumors using Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates (VDCs). The Company's VDC platform offers a range of portfolio of targeted oncology therapeutics. It engaged in developing AU-011 for the treatment of early-stage disease, which includes small melanomas and indeterminate lesions. Its product candidate, AU-011 consists of a human papilloma virus (HPV)-derived VLP conjugated to thousands of infrared laser-activated molecules. VDC prevents the conjugation from interfering with tumor binding enabling its selectivity to specifically modified HSPGs on tumor cells but not to normal cells. In addition, the Company is developing AU-011 for the treatment of non-muscle invasive bladder cancer (NMIBC).